Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
about
Sclerostin Inhibition in the Management of OsteoporosisRecent developments in osteogenesis imperfectaEffect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatmentLRP receptor family member associated bone diseaseSclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfectaOsteocyte-specific WNT1 regulates osteoblast function during bone homeostasisModeling craniofacial and skeletal congenital birth defects to advance therapies.Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.Application of anti-Sclerostin therapy in non-osteoporosis disease models.Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl/+ osteogenesis imperfecta mouse model.Osteogenesis imperfecta and therapeutics.New frontiers for dominant osteogenesis imperfecta treatment: gene/cellular therapy approachesTreatment options for osteogenesis imperfecta
P2860
Q26750713-B1681EB1-4098-4EEB-B7C0-9E8A2AC3FE31Q26781674-CBDEAB8B-158B-46CD-87EF-410A695C6E06Q30713102-1FF4574B-80CA-4A5A-85C9-E84AE16CC644Q34759279-0C99547E-EEFC-4457-87B0-B95A8BD6FDDAQ36005849-75374C85-3A1E-4D76-AC1E-BF2112FDF5F7Q36889245-45693B65-96EE-42F2-81E5-AE7402B9C226Q36889250-06BBDB0D-8476-4ED4-A6D7-B406B3A8D8B8Q38719412-1225ED23-7EC5-4C5F-B096-810DA2956D6CQ38877817-C906908B-EE40-417B-8711-BCFA906B01B4Q38998578-1128D073-BE5F-4B57-9AF6-0ADD71B93625Q47099469-0EF235FF-0673-4690-8A30-18D80FCBA2A9Q48332923-8CA2A29D-CD38-430D-8D5C-96E27FC01534Q51363424-CC618267-9C67-45FF-BAE2-B31BE3C8507CQ52653933-AF8E31D2-DD90-45FA-9677-65F0543FFFC0Q52655586-46B91C55-2FF5-4056-8D27-E168A59F97B6Q58270335-43B56DDC-D780-4673-898C-9190CD052FE0Q58752199-1C165B39-312D-4DEC-B90E-2EDA19E019BB
P2860
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@ast
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@en
type
label
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@ast
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@en
prefLabel
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@ast
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@en
P2093
P2860
P1476
Adult Brtl/+ mouse model of os ...... reased bone mass and strength.
@en
P2093
B P Sinder
J C Marini
J D Salemi
K M Kozloff
M S Ominsky
P2860
P2888
P304
P356
10.1007/S00198-014-2737-Y
P407
P577
2014-05-07T00:00:00Z